Insulin 2019 – Global Intelligence Center Database with Coverage from 2012 to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Insulin
Intelligence Center 2012-2023” report has been added to ResearchAndMarkets.com’s
offering.

The Insulin Intelligence Center is a global intelligence
database platform, which provides data, covering five regions with
in-depth analysis across 25 countries with a five-year forecast,
including value, volume sales, price, and price per capita expenditure.

The intelligence center enhances your understanding of the human insulin
drugs market. The market is also assessed considering the economic
factors, such as Type-1 diabetic population level, Type-2 diabetic
population level, and obesity, which will provide you with actionable
business insights.

Market Scope

• The human insulin drugs market data, volume, and value analytics with
  growth trends (2012-2023).
• Branded and biosimilar drugs data for 2012-2023.
• Market indicators – Diabetic population levels, diabetes disease
  prevalence, diabetic Type-1 population level, diabetic Type-2
  population level, and per capita expenditure.
• The IC for human insulin drugs provides exhaustive coverage (countries
  covered account for more than 80% of the overall spending on
  diabetes), covering two categories, six segments, and tracking of over
  10,000 data points.

Categories

• Branded Insulin Drugs
• Biosimilar Insulin Drugs

Segments

• Basal Insulin or Long-acting Insulin
• Bolus Insulin or Fast-acting Insulin
• Pre-mixed Insulin or Combination Insulin
• Traditional Human Insulin
• Traditional Human Insulin Biosimilars
• Insulin Glargine Biosimilars

Market Overview

• The global human insulin drugs market is expected to register a CAGR
  of 4.93% during the forecast period (2018-2023), and was valued at USD
  24 billion by 2018.
• Diabetes is generally considered as a lifestyle-related disease. Over
  time, incidences of the disease have increased outrageously, with the
  increase in global population. Approximately, 100 million people
  around the world need insulin, including all the people suffering from
  Type-1 diabetes and between 10%-25% of people suffering from Type-2
  diabetes.
• Although insulin has been used in the treatment of diabetes for over
  90 years, globally, more than half of those who need insulin today
  still cannot afford and access it. People suffering from Type-1
  diabetes need insulin therapy, which focuses on managing blood sugar
  levels, along with insulin, diet, and lifestyle, in order to prevent
  complications.

Insulin Drugs Under Development

• Novo Nordisk is developing a first once-weekly long-acting insulin
  (LAI287), which is currently in phase 2. The insulin is indicated for
  both Type-1 and Type-2 diabetic population levels.
• Eli Lilly is developing a long-acting insulin-Fc (LY3209590). “Basal
  insulin-Fc” is a large molecule comprised of engineered insulin fused
  to an Fc domain, designed to provide a long-acting basal profile.
  LY3209590 is being studied for the treatment of diabetes.

Oral Insulin’s Drugs will boost the market

• Biocon is developing Insulin Tregopil, an oral prandial insulin
  tablet, for the treatment of Type-1 and Type-2 diabetes mellitus. The
  fast-acting oral insulin may improve post-prandial glucose control
  with reduced side effects and greater adherence, thus, holding the
  promise to transform Type-1 diabetes management.
• Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company,
  focused on the development of oral drug delivery systems, is working
  to bring the first oral insulin product to market, thus, providing a
  more convenient, effective, and safer method for delivering insulin
  therapy.

Reasons to Purchase this Dashboard

• More Granular: Covers more categories, segments, and information on
  brands at country- and global levels than the other market
  intelligence providers
• Provides an outlook of the market with recent market and historical
  data and market forecast
• Ease of Comparability: Analytics are based on the standardized
  definition across the world, in order to facilitate better
  comparability of market data
• View the market in different ways among categories and geography to
  understand where the actual opportunity lies
• Market segmentation, including quantitative research, incorporating
  the impact of economic and non-economic aspects
• Regional- and country-level data integrating the demand and supply
  forces that are influencing the growth of the market
• Market value (in USD million) and volume (in ml million) data for each
  segment and sub-segment
• Understanding of the market, due to value and volume changes,
  intra-category competition
• Dedicated analyst support for research queries and training
• Continuous amendment of a yearly database with significant changes,
  updated based on scenarios

Countries Covered

• United States
• Canada
• France
• Germany
• Italy
• Spain
• United Kingdom
• Russia
• Mexico
• Brazil
• Japan
• South Korea
• China
• India
• Australia
• Vietnam
• Malaysia
• Indonesia
• Philippines
• Thailand
• Saudi Arabia
• Iran
• Egypt
• Oman
• South Africa

Companies Mentioned

• Eli Lilly
• Novo Nordisk
• Sanofi

List of Topics Covered

1. Introduction

1.1 Key Deliverables of the Study

1.2 Market Definition

2. Research Approach and Methodology

2.1 Introduction

2.2 Research Designs

2.3 Study Phases

2.3.1 Internal sources evaluation

2.3.2 Research Process

2.3.3 Modeling & triangulation

2.3.4 Data finalization

2.3.5 Expert Validation

3. Market Segmentation

3.1 By Drug

3.1.1 Insulin

3.2 Geography

3.2.1 North America

3.2.2 Europe

3.2.3 Latin America

3.2.4 Asia-Pacific

3.2.5 Middle East and Africa

4. Market Indicators

4.1 Type-1 Diabetes population (2012-2023)

4.2 Type-2 Diabetes population (2012-2023)

5. Company Share Analysis

For more information about this report visit https://www.researchandmarkets.com/research/zn7xd5/insulin_2019?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs